Electrospun Drug-Loaded and Gene-Loaded Nanofibres: The Holy Grail of Glioblastoma Therapy?

Lynn Louis, Bor shin Chee, Marion McAfee, Michael Nugent

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

To date, GBM remains highly resistant to therapies that have shown promising effects in other cancers. Therefore, the goal is to take down the shield that these tumours are using to protect themselves and proliferate unchecked, regardless of the advent of diverse therapies. To overcome the limitations of conventional therapy, the use of electrospun nanofibres encapsulated with either a drug or gene has been extensively researched. The aim of this intelligent biomaterial is to achieve a timely release of encapsulated therapy to exert the maximal therapeutic effect simultaneously eliminating dose-limiting toxicities and activating the innate immune response to prevent tumour recurrence. This review article is focused on the developing field of electrospinning and aims to describe the different types of electrospinning techniques in biomedical applications. Each technique describes how not all drugs or genes can be electrospun with any method; their physico-chemical properties, site of action, polymer characteristics and the desired drug or gene release rate determine the strategy used. Finally, we discuss the challenges and future perspectives associated with GBM therapy.

Original languageEnglish
Article number1649
JournalPharmaceutics
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 2023

Keywords

  • electrospinning
  • electrospun nanofibres
  • glioblastoma (GBM)

Fingerprint

Dive into the research topics of 'Electrospun Drug-Loaded and Gene-Loaded Nanofibres: The Holy Grail of Glioblastoma Therapy?'. Together they form a unique fingerprint.

Cite this